Overview

COVID-19 Reactogenicity

Status:
NOT_YET_RECRUITING
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare post-vaccination reactions between the protein-based Novavax vaccine and the mRNA Pfizer vaccine. Specifically, the study aims to determine the rate of participant-reported symptoms associated with each type of vaccine.
Phase:
PHASE4
Details
Lead Sponsor:
Marcel Curlin
Treatments:
BNT162 Vaccine
NVX-CoV2373 adjuvated lipid nanoparticle